Question

Will a small molecule GLP-1-based drug be approved for the treatment of obesity by the FDA or EMA by 2029?

5 comments5

Total Forecasters36

Community Prediction59.7%

Make a Prediction

50%

community: 59.7%

median 59.7%mean 58.3%

Authors:

casens

Opened:

Closes:

Scheduled resolution:

Food and Drug Administration

Scientific breakthrough to prevent negative side effects of weight loss drugs like Ozempic

Independent•Nov 14, 2024

New weight loss drug decreases appetite without nausea — and can even burn calories

New York Post•Nov 14, 2024

Is this the new Ozempic? Scientists develop weight loss drug that reduces appetite but DOESN'T make you feel sick

Daily Mail•Nov 14, 2024

Learn more about Metaculus NewsMatch

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

80.8%

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

43%

Comments

? comments

Authors:

casens

Opened:

Closes:

Scheduled resolution:

Food and Drug Administration

Scientific breakthrough to prevent negative side effects of weight loss drugs like Ozempic

Independent•Nov 14, 2024

New weight loss drug decreases appetite without nausea — and can even burn calories

New York Post•Nov 14, 2024

Is this the new Ozempic? Scientists develop weight loss drug that reduces appetite but DOESN'T make you feel sick

Daily Mail•Nov 14, 2024

Learn more about Metaculus NewsMatch

Will oral semaglutide be approved for the treatment of obesity by the FDA or EMA by 2027?

80.8%

Will the FDA or EMA withdraw approval of Semaglutide for the treatment of obesity by 2027?

Will the combination of semaglutide and cagrilintide be approved for the treatment of obesity by the FDA or EMA by 2027?

43%